糖尿病肾病多学科诊治与管理专家共识

2020-05-07 中国临床医生杂志.2020,48(5):522-527.

临床上,糖尿病患者出现蛋白尿或肾小球滤过率(glomerular filtration rate,GFR) 下降, 并不能诊断DKD。在2 型糖尿病患者中只有30% ~ 40%的患者才罹患糖尿病肾病,

中文标题:

糖尿病肾病多学科诊治与管理专家共识

发布机构:

发布日期:

2020-05-07

简要介绍:

临床上,糖尿病患者出现蛋白尿或肾小球滤过率(glomerular filtration rate,GFR) 下降, 并不能诊断DKD。在2 型糖尿病患者中只有30% ~ 40%的患者才罹患糖尿病肾病,大部分糖尿病患者不发展为糖尿病肾病。因此,糖尿病患者出现蛋白尿或GFR 下降, 首先必须明确是DKD, 还是糖尿病合并了其他肾病(non-diabetic kidney disease,NDKD), 亦或是DKD 和NDKD 并存, 需要依靠肾病专科医师来鉴别,通常需要肾活检病理来区分诊断。DKD 及其他糖尿病并发症的防治,需要内分泌科、肾内科、心内科、神经内科和眼科等多学科合作,因此,以肾病科为主的多学科合作是DKD 防治的理想模式。根据临床经验并结合国内外最新文献, 我们制订了DKD 临床多学科诊治和管理的共识。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=糖尿病肾病多学科诊治与管理专家共识_姜世敏.pdf)] GetToolGuiderByIdResponse(projectId=1, id=29cd31c00190e767, title=糖尿病肾病多学科诊治与管理专家共识 , enTitle=, guiderFrom=中国临床医生杂志.2020,48(5):522-527., authorId=0, author=, summary=临床上,糖尿病患者出现蛋白尿或肾小球滤过率(glomerular filtration rate,GFR) 下降, 并不能诊断DKD。在2 型糖尿病患者中只有30% ~ 40%的患者才罹患糖尿病肾病,, cover=https://img.medsci.cn/2020517/1589727272088_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu May 07 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>临床上,糖尿病患者出现蛋白尿或肾小球滤过率(glomerular filtration rate,GFR) 下降, 并不能诊断DKD。在2 型糖尿病患者中只有30% ~ 40%的患者才罹患糖尿病肾病,大部分糖尿病患者不发展为糖尿病肾病。因此,糖尿病患者出现蛋白尿或GFR 下降, 首先必须明确是DKD, 还是糖尿病合并了其他肾病(non-diabetic kidney disease,NDKD), 亦或是DKD 和NDKD 并存, 需要依靠肾病专科医师来鉴别,通常需要肾活检病理来区分诊断。DKD 及其他糖尿病并发症的防治,需要内分泌科、肾内科、心内科、神经内科和眼科等多学科合作,因此,以肾病科为主的多学科合作是DKD 防治的理想模式。根据临床经验并结合国内外最新文献, 我们制订了DKD 临床多学科诊治和管理的共识。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1391, tagName=糖尿病肾病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1391, guiderKeyword=糖尿病肾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4982, appHits=660, showAppHits=477, pcHits=1586, showPcHits=4743, likes=10, shares=42, comments=40, approvalStatus=1, publishedTime=Sun May 17 23:03:59 CST 2020, publishedTimeString=2020-05-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun May 17 22:54:39 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 14:01:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=糖尿病肾病多学科诊治与管理专家共识_姜世敏.pdf)])
糖尿病肾病多学科诊治与管理专家共识_姜世敏.pdf
下载请点击:
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1230512, encodeId=76fc1230512a4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Mon Jul 04 17:06:03 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227950, encodeId=6468122e950df, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Wed Jun 22 10:32:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054525, encodeId=84bf1054525ec, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3855616308, createdName=ms7000001060489169, createdTime=Fri Sep 24 20:13:03 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973270, encodeId=09939e327059, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Sun Jun 13 14:09:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962835, encodeId=8976962835d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91b34854656, createdName=1635161771, createdTime=Wed May 05 16:40:36 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2022-07-04 ms6000000755974223

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1230512, encodeId=76fc1230512a4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Mon Jul 04 17:06:03 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227950, encodeId=6468122e950df, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Wed Jun 22 10:32:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054525, encodeId=84bf1054525ec, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3855616308, createdName=ms7000001060489169, createdTime=Fri Sep 24 20:13:03 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973270, encodeId=09939e327059, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Sun Jun 13 14:09:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962835, encodeId=8976962835d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91b34854656, createdName=1635161771, createdTime=Wed May 05 16:40:36 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2022-06-22 ms6000000755974223

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1230512, encodeId=76fc1230512a4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Mon Jul 04 17:06:03 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227950, encodeId=6468122e950df, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Wed Jun 22 10:32:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054525, encodeId=84bf1054525ec, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3855616308, createdName=ms7000001060489169, createdTime=Fri Sep 24 20:13:03 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973270, encodeId=09939e327059, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Sun Jun 13 14:09:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962835, encodeId=8976962835d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91b34854656, createdName=1635161771, createdTime=Wed May 05 16:40:36 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2021-09-24 ms7000001060489169

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1230512, encodeId=76fc1230512a4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Mon Jul 04 17:06:03 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227950, encodeId=6468122e950df, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Wed Jun 22 10:32:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054525, encodeId=84bf1054525ec, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3855616308, createdName=ms7000001060489169, createdTime=Fri Sep 24 20:13:03 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973270, encodeId=09939e327059, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Sun Jun 13 14:09:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962835, encodeId=8976962835d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91b34854656, createdName=1635161771, createdTime=Wed May 05 16:40:36 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2021-06-13 12192b1am98暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1230512, encodeId=76fc1230512a4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Mon Jul 04 17:06:03 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227950, encodeId=6468122e950df, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34446512602, createdName=ms6000000755974223, createdTime=Wed Jun 22 10:32:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054525, encodeId=84bf1054525ec, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3855616308, createdName=ms7000001060489169, createdTime=Fri Sep 24 20:13:03 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973270, encodeId=09939e327059, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Sun Jun 13 14:09:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962835, encodeId=8976962835d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91b34854656, createdName=1635161771, createdTime=Wed May 05 16:40:36 CST 2021, time=2021-05-05, status=1, ipAttribution=)]
    2021-05-05 1635161771

    0

拓展阅读

2011 糖尿病肾病中医防治指南

中华中医药学会(CACM,China Association of Chinese Medcine) · 2011-02-20

糖尿病肾病防治专家共识(2014年版)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-11-20

糖尿病肾脏病诊治专家共识

暂未更新 · 2020-02-04

中药新药用于糖尿病肾脏疾病临床研究技术指导原则(征求意见稿)

国家药品监督管理局药品审评中心(CDE) · 2019-05-30

SGLT2i对糖尿病肾病治疗获益共识 2020

孟加拉国内分泌协会(Endocrine Society of Bengal) · 2020-10-13

2020 APSN临床实践指南:糖尿病肾病

肾脏病相关专家小组(统称) · 2020-10-25